Jorge Bertran-Pasarell, MD
Infectious Disease · Hato Rey, PRNPI 1578560702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,245 of the $63,832 with a category attached, or 85.0%. AbbVie accounts for 89.5% of it on its own, with 9 other manufacturers making up the rest. Among infectious disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $651.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$57K
- Merck$6K
- Shionogi Inc$241
- Verity Pharmaceuticals Inc.$123
- PBG Puerto Rico LLC$115
- Boehringer Ingelheim$100
- plus $164 from 4 others
Across 1 payment — averaging $462.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$463
What the payments were for
- Consulting fees$6,35010%
- Speaking & faculty fees$54,24585%
- Food & beverage$3,2375%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $57,136 |
| Merck | 7 | $5,953 |
| Shionogi Inc | 2 | $241 |
| Verity Pharmaceuticals Inc. | 1 | $123 |
| PBG Puerto Rico LLC | 5 | $115 |
| Boehringer Ingelheim | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 2 | $55 |
| Johnson & Johnson | 1 | $45 |
| Gilead | 1 | $40 |
| AstraZeneca | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,832 in reported general payments places this provider in the 95th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 11 | $2,377 |
| Ivermectin | 34 | $760 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $396 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $315 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Hato Rey
- Marisel Bosques RosadoHato Rey$247K
- Arelis Febles NegronHato Rey$1K
- Jorge Santana BagurManati$180K
- Francisco AlvaradoCaguas$69K
- Joel Munoz CoreanoBayamon$59K
- Vanessa Olivo EchavarrySan Juan$41K
- Carlos Guzman OrtizAibonito$38K
- Angeles Rodriguez RosaSan Juan$27K
- Miguel Colon PerezSan Juan$12K
- Yolanda Rodriguez-RamirezAibonito$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.